Where would you like to sign in?

Microbix Announces Annual and Special Meeting Voting Results

TORONTO, ONTARIO--(Marketwired - March 6, 2015) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, announces the results of the Annual and Special Meeting of Shareholders which was held on March 3, 2015, at which 46.64% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in the Company's Information Circular, which was filed on SEDAR on February 10, 2015. All of the nominees listed in the Information Circular were re-elected as directors of Microbix. Detailed results of the vote are set out below:

Nominee

For

% For

Withheld

% Withheld

Peter M. Blecher

32,768,754

98.07

645,923

1.93

Mark A. Cochran

32,705,954

97.88

708,723

2.12

Vaughn C. Embro-Pantalony

32,712,754

97.90

701,923

2.10

William J. Gastle

32,541,154

97.39

873,523

2.61

Andrew C. Pollock

32,705,954

97.88

708,723

2.12

Joseph D. Renner

32,802,754

98.17

611,923

1.83

Martin Marino

32,755,954

98.03

658,723

1.97

Cameron Groome

32,802,754

98.17

611,923

1.83

In addition, shareholders approved: the appointment of the Company's auditors; Collins Barrow Toronto LLP, amendments to the Company's stock option plan; and amendments to warrants held by insiders.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the development of biological solutions, including products for vaccine and diagnostics markets worldwide. The company owns intellectual property for an approved biological drug, a vaccine technology and an animal reproduction technology. Established in 1988, Microbix is headquartered in Toronto.

Microbix' pipeline of innovative technologies and products includes LumiSort® semen sexing technology for the livestock industry, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in influenza vaccine manufacture.